Thymosin α1 Reduces Pneumonia in Lung Cancer Patients Undergoing Chemoradiotherapy

Non-small cell lung cancer (NSCLC) is a common and aggressive malignancy, often treated with intensive chemoradiotherapy. This treatment, particularly in patients with bulky tumors, frequently leads to severe side effects such as acute pneumonia and radiation pneumonitis, which can significantly impact patient quality of life, treatment adherence, and overall survival. This Phase II study aimed to investigate whether the immunomodulatory peptide Thymosin α1 could effectively reduce the incidence and severity of these treatment-related lung toxicities in NSCLC patients.